AUR103 calcium + trastuzumab + capecitabine + oxaliplatin

AUR103 calcium + trastuzumab + capecitabine + oxaliplatin is an investigational combination regimen under study for the treatment of HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. This regimen includes four distinct agents: AUR103 calcium, an oral small molecule inhibitor of CD47 (a “don’t eat me” signal on tumor cells); trastuzumab, a monoclonal antibody targeting the HER2 receptor; capecitabine, an oral prodrug of 5-fluorouracil interfering with DNA synthesis; and oxaliplatin, a platinum-based chemotherapeutic agent causing DNA crosslinking. The combination aims to leverage immune-mediated antitumor effects (CD47 and HER2 blockade), alongside cytotoxic chemotherapy, to enhance efficacy in HER2-positive cancers[1][2][4].